UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 104

Sortiert nach

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC cancer, 2016-07, Vol.16 (1), p.420-420, Article 420

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC cancer, 2016-07, Vol.16 (1)

2016

Link zum Volltext

Verfügbarkeit prüfen

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

British journal of cancer, 2007-04, Vol.96 (7), p.1013-1019

2007

Link zum Volltext

Verfügbarkeit prüfen

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

British journal of cancer, 2007-08, Vol.97 (3), p.315-321

2007

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

Bone marrow transplantation (Basingstoke), 2009-03, Vol.43 (5), p.383-397

2009

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

Bone marrow transplantation (Basingstoke), 2009-03, Vol.43 (5), p.383-397

2009

Link zum Volltext

Verfügbarkeit prüfen

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

British journal of cancer, 2000-07, Vol.83 (2), p.261-266

2000

Link zum Volltext

Verfügbarkeit prüfen

Influence of Catumaxomab on Tumor Cells in Bone Marrow and Blood in Ovarian Cancer

Anticancer research, 2009-05, Vol.29 (5), p.1787-1791

2009

Link zum Volltext

Verfügbarkeit prüfen

Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies ({{alpha}}EpCAM {{alpha}}CD3)

The journal of histochemistry and cytochemistry, 2001-07, Vol.49 (7), p.911-917

2001

Link zum Volltext

Verfügbarkeit prüfen

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes

International journal of oncology, 2004-10, Vol.25 (4), p.841

2004

Link zum Volltext

Verfügbarkeit prüfen

8007 ORAL Catumaxomab Induces Efficient Anti-tumour Activity in Vitro With Immune Cells From Ovarian Cancer Patients After Chemotherapy Treatment

European journal of cancer (1990), 2011, Vol.47, p.S529-S529

2011

Link zum Volltext

Verfügbarkeit prüfen

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

Blood, 2001-10, Vol.98 (8), p.2526-2534

2001

Link zum Volltext

Verfügbarkeit prüfen

Combined Treatment of Metastatic Breast Cancer (MBC) by High-dose Chemotherapy (HDCT) and Bispecific Antibodies: A Pilot Study

Anticancer research, 2005-07, Vol.25 (4), p.3047-3054

2005

Link zum Volltext

Verfügbarkeit prüfen

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma

Annals of oncology, 2006-12, Vol.17 (12), p.1830-1834

2006

Link zum Volltext

Verfügbarkeit prüfen

Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy

European urology open science (Online), 2022-11, Vol.45, p.S234-S235

2022

Link zum Volltext

Verfügbarkeit prüfen

1313 Catumaxomab treatment reduces VEGF protein levels within malignant ascites: data from a pivotal phase II/III study

European journal of cancer supplements, 2009, Vol.7 (2), p.142-143

2009

Link zum Volltext

Verfügbarkeit prüfen

1312 Catumaxomab therapy eliminates putative CD133+ EpCAM+ cancer stem celles from malignant ascites: data from a pivotal phase II/III study

European journal of cancer supplements, 2009, Vol.7 (2), p.142-142

2009

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer

Journal of Gynecologic Oncology, 2014, 25(3), , pp.221-228

2014

Link zum Volltext

Verfügbarkeit prüfen

6507 Catumaxomab treatment in gastric-cancer patients with malignant ascites – subgroup-analysis of a pivotal trial

European journal of cancer supplements, 2009, Vol.7 (2), p.363-363

2009

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy of malignant ascites with trifunctional antibodies

International journal of cancer, 2005-11, Vol.117 (3), p.435-443

2005

Link zum Volltext

Verfügbarkeit prüfen

Lasting remission following multimodal treatment in a patient with metastatic breast cancer

Anti-cancer drugs, 2005-11, Vol.16 (10), p.1135-1137

2005

Link zum Volltext

Verfügbarkeit prüfen

Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer

International journal of gynecological cancer, 2013-06, Vol.23 (5), p.797-802

2013

Link zum Volltext

Verfügbarkeit prüfen

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes

Blood, 2006-02, Vol.107 (4), p.1564-1569

2006

Link zum Volltext

Verfügbarkeit prüfen

Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2575-2575

2011

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

The Journal of immunology (1950), 1999-08, Vol.163 (3), p.1246-1252

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(79)

Publikationsform

Artikel
(101)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(41)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Middle Aged
(24)
Female
(21)
Male
(21)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Oncology
(18)
Immunotherapy
(16)
Adult
(15)
Animals
(13)
Mice
(13)
Tumors
(11)
Antineoplastic Agents
(10)
Lipoproteins - Blood
(10)
Pharmacology. Drug Treatments
(10)
Aged
(9)
Antibodies, Bispecific - Therapeutic Use
(9)
Cholesterol - Blood
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

Influence of Catumaxomab on Tumor Cells in Bone Marrow and Blood in Ovarian Cancer

Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies ({{alpha}}EpCAM {{alpha}}CD3)

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes

8007 ORAL Catumaxomab Induces Efficient Anti-tumour Activity in Vitro With Immune Cells From Ovarian Cancer Patients After Chemotherapy Treatment

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

Combined Treatment of Metastatic Breast Cancer (MBC) by High-dose Chemotherapy (HDCT) and Bispecific Antibodies: A Pilot Study

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma

Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy

1313 Catumaxomab treatment reduces VEGF protein levels within malignant ascites: data from a pivotal phase II/III study

1312 Catumaxomab therapy eliminates putative CD133+ EpCAM+ cancer stem celles from malignant ascites: data from a pivotal phase II/III study

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer

6507 Catumaxomab treatment in gastric-cancer patients with malignant ascites – subgroup-analysis of a pivotal trial

Immunotherapy of malignant ascites with trifunctional antibodies

Lasting remission following multimodal treatment in a patient with metastatic breast cancer

Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes

Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites

Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

Suchergebnisse filtern